利培酮、喹硫平、齐拉西酮对首发女性精神分裂症患者妊娠的影响

发布时间：2018-02-24 07:13

  本文关键词： 精神分裂症 首发 妊娠 利培酮 喹硫平 齐拉西酮 妊娠结局　出处：《基因组学与应用生物学》2017年04期 　论文类型：期刊论文

【摘要】：探讨利培酮、喹硫平和齐拉西酮对首发女性精神分裂症妊娠患者糖脂代谢及妊娠结局的影响。选取2012年7月~2014年7月我院收治的首发精神分裂症孕妇97例作为研究对象,根据治疗方案分为利培酮组(27例)、喹硫平组(36例)、齐拉西酮组(34例),均治疗8周。记录临床疗效、不良用药反应和不良妊娠结局,治疗前后采用阳性和阴性综合征量表(PANSS)、简明精神病量表(BPRS)检测精神分裂症严重程度,检测治疗前后体质量(BMI)及糖脂水平。结果发现,3组患者临床疗效、妊娠结局、不良用药反应比较无明显差异(p0.05),3组治疗后PANSS、BPRS评分均下降,差异具有统计学意义(p0.05),但3组治疗后组间比较无差异(p0.05);3组患者治疗前后空腹血糖(FPG)、餐后2 h血糖(2h PBG)、胆固醇(TC)无明显变化(p0.05);3组治疗后BMI、血清胰岛素(FINS)、甘油三酯(TG)均有所改变,同组治疗前后差异显著(p0.05);其中喹硫平组BMI上升幅度较齐拉西酮组明显(p0.05),利培酮组FINS下降,喹硫平组、齐拉西酮组均上升,利培酮组FINS低于喹硫平组、齐拉西酮组,差异有统计学意义(p0.05)。因此,利培酮、喹硫平、齐拉西酮对首发女性精神分裂症孕妇的精神分裂症状改善疗效一致,但易致糖脂代谢紊乱,存在一定风险。
[Abstract]:To investigate the effects of risperidone, quinolipine and ziprasidone on glucose and lipid metabolism and pregnancy outcome in first-episode female schizophrenic pregnancy, 97 first-episode schizophrenic pregnant women admitted to our hospital from July 2012 to July 2014 were selected as subjects. The patients were divided into risperidone group (n = 27), quetiapine group (n = 36) and ziprasidone group (n = 34) for 8 weeks. Positive and negative syndrome scale (PANSS), brief Psychiatric scale (BPRS) were used before and after treatment to detect the severity of schizophrenia, body mass and serum glucose and lipid levels before and after treatment. There was no significant difference in adverse drug reactions among the three groups. After treatment, the scores of PANSS and BPRS were all decreased. The difference was statistically significant (P 0.05), but there was no significant difference between the three groups after treatment. There was no significant change in fasting blood glucose (FBG) before and after treatment, 2 h postprandial blood glucose (2 h PBGG), and no significant change in cholesterol (TCc) after treatment. There were no significant changes in BMIs, serum insulin and triglyceride (TG) levels in the three groups after treatment. There was a significant difference between the same group before and after treatment (p 0.05), in which the increase of BMI was significantly higher in quetiapine group than in ziprasidone group, the FINS in risperidone group was decreased, and the FINS in risperidone group was lower than that in ziprasidone group, and the FINS in risperidone group was lower than that in ziprasidone group. Therefore, risperidone, quetiapine and ziprasidone have the same effect on the improvement of schizophrenic symptoms in first-episode female schizophrenic women, but they are prone to lead to disorder of glucose and lipid metabolism, and there are certain risks.
【作者单位】： 武汉市精神卫生中心;
【基金】：武汉市卫生局课题资助(WX08D21)资助
【分类号】：R714.2;R749.3
，

本文编号：1529338